Influenza Vaccines Market Research Report - Global Forecast till 2027

Influenza Vaccines Market: Information by Influenza Type (Seasonal and Zoonotic), by Manufacturing Technology (Egg-based, Cell culture-based and Recombinant-based), by Vaccine Type ( Quadrivalent Influenza Vaccines and Trivalent Influenza Vaccines) by End User (Hospitals & Clinics, Research Organizations & Academic Institutes, and others) and by Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/1090-CR | January, 2020 | Region : Global

Influenza Vaccines Market Overview:
The global influenza vaccines market is predicted to reach USD 7,828.3 Million by 2025 to register a CAGR of 6.53%.  The influenza virus is a very common and deadly viral infection with the potential of infecting the respiratory system of human beings. The influenza virus is a contagious respiratory illness that affects the lungs, nose, and throat.  People who have week immunity systems or who have chronic diseases are at high risks. It is a viral disease that spreads from one person to another in oozing of the lungs and nose.


Vaccines work with the body’s natural defense to fabricate protection by reducing the risks of getting infected. A vaccine helps to produce the antibodies in the immunity system to fight the diseases. One or more doses of the vaccine typically protect against the diseases for a few years, decades, or maybe even for a lifetime. There is mostly two influenza vaccine type which is widely available in the market, these are inactivated influenza vaccine (IIV) and live attenuated influenza vaccines (LAIV). These vaccines are made to protect against three seasonal viruses. Influenza viruses are a threat to the human population, under the major public health estimation; vaccinations are the ultimate prevention from the disease.


The influenza vaccine market size is estimated to reach nearly $6.20 Billion by the end of 2026; it was estimated at nearly $3.96 Billion in the year 2018, with an increasing annual growth rate of 5.9% (CAGR) in between 2019 to 2026. According to the static data from the centers for disease control and prevention, there are more than 13 million flu cases that are documented till now, in between the time frame of 2019 to 2020. Depending on the current scenario of the vaccine market, the licensed seasonal vaccines are recommended by government organizations, centers for disease control and prevention, and by the world health organization. Pharmaceutical companies are continuously working on improving the condition of the vaccines against different infections. The urge of rising demands increases the global influenza vaccine market value.


This report focuses on the all-inclusive global flu vaccine market and the strength of the influenza vaccine market. Along with that, the report contains the high points of dynamics, segmentation, key players, regional analysis, and many other factors. The report also included a detailed analysis of the influenza vaccine globally and forecasts to 2025.


Covid 19 Analysis:
The increasing demand for vaccines has bolstered the growth of the influenza market size. The outbreak of the pandemic has affected the countries around the globe tremendously; this has affected the global market of vaccination. There is a rise in the demand for vaccines globally because of the effectiveness of the doses against the disease or infection. There was a report issued at the starting of the year 2020 by Pfizer. Inc that there were no disturbances accrued in the supply chain of these vaccines in fact the emission of covid 19 vaccines has raised the potential value of the influenza vaccine market.


According to the researchers of Brazil, these vaccine shots can help to reduce the death rates by 20 % before the inception of the covid vaccine and it can reduce about 27 % after the inception of the covid vaccine. Thus the analyst believes that these factors can toss the demand for this influenza vaccine.


Market Dynamic:



  •         Drivers


The influenza vaccine market has increased tremendously over the past few years. There is a number of factors influencing the raised market value including the increase of the awareness of the disease among the people, funding, and the fear of influenza pandemic.


There are seven major markets that have a strong amalgamation of the annual growth rate of 12.65%, it includes UK, France, Germany, the united states, Japan, Spain, and Italy.



  •         Opportunities


The government has taken the initiative to sure the well-being of the population by minimizing the side effects of the influenza vaccines. The development of new vaccines and the improvement of the existing or current vaccines are the major causes for the rise of the influenza vaccine market.


Along with that, the rise in the population, investment, and funding by different companies are also directly linked with the expansion of the influenza vaccine market growth.  



  •         Restraints


69,009 people were diagnosed in the year 2018 with the influenza virus. Among which 67,733 people have diagnosed with influenza A virus and the rest of them were diagnoses with influenza B virus. In the United States, the cases of influenza have increased from 9.2 Million cases to 49.0 million cases of infection in 2010.


The inactivated influenza vaccines (IIV) are appropriate for younger people, most probably for kids of 6 months or above. The recombinant influenza vaccine is only acceptable for adults or people aged 18 years or more. The adjuvant vaccines contain the highest doses, hence approved for older people or people aged 65 years or more.   



  •         Challenges


The influenza market is facing a number of challenges due to Covid 19 and several other seasons.  There is a specific period of time in which the seasonal vaccines should be produced and shipped; the approx time frame is of 6 months. The delays in the manufacturing of the vaccines can mislay market shares and the revenue.


The demands of the vaccine vary according to the season, weather, and timing which affect the growth in the market. The availability of influenza vaccines during the unpredictable period is the major provocation in the market. The awareness among the public is another one.



  •         Cumulative Growth Analysis


The global influenza market expected to reach up to USD 7,321.79 Million in 2025 from USD 5,563.37 Million USD in 2019 with an annual growth rate of 4.86%.


The growth on the demand depends upon the four major segments that include influenza type, technology, manufacturing, and end user. Thereafter, the market growth can get affected by a pandemic or calamitous conditions or natural disaster.  


Value Chain Analysis:
There are four segments of the influenza market that are typically based on the different influenza type, vaccine type, manufacturing technology, and end user. On the basis of the type the influenza vaccines have been bifurcated into zoonitic and seasonal. On the other hand, on the basis of manufacturing technology, the vaccine has been categorized into egg-based, cell-culture based, recombinant based. According to the type of vaccine, it is bifurcated into trivalent vaccine and quadrivalent vaccine. The end-users of the global influenza market can be research organizations, academic institutions, hospitals, and others.


The form of the dosage can be nasal spray, intramuscular injection and intradermal. The report contains the market trends related with each segment and affects of the segments on the overall growth of the global influenza vaccines market.   


Segmentation Overview:
On the basis of the end users and application the global influenza vaccines market can be categorized. According to the different products, there are two different types of vaccines; one is trivalent vaccine and quadrivalent vaccines.



  •         By Application


On the application basis, the vaccines are segmented into two types, one is trivalent vaccine which is for the kids of 6 months or above and the other one is recombinant influenza vaccine, which is for the adults or for the aged people.  


Hence, the effects of the virus changes slightly every year, that makes the vaccines of previous year less effective or ineffective. This is the major cause of the fluctuation in the global vaccine market. 



  •         By End-Users


On the basis on the End-user segmentation, the global influenza vaccination is modified by different sectors including academic institutes, clinics and hospitals, researchers and organizations, and others. 


There are chance is highest growth in the research sector during the projected period. The reason for that is the nature of the virus which is changing every year and accordingly the vaccines needs up gradation after every 6 months to 1 year.


Regional Analysis:
The influenza vaccine market is divided into four sections, based on the region and which are Europe, America, the Middle East & Africa, and Asia-pacific. The America is leading the race; it has dominated the global influenza vaccine market with an attribution of more than half of the population. Each year, 5% to 20% of the total population suffers from the influenza virus.


European markets are the second largest market for the global influenza vaccine market during the review period. The generality of the influenza and the rise in the product has boosted the growth of the regional market. The uptakes of the vaccines have increased to 72% from 2018 to 2019, from 70% from 2016 to 2017.


The Pacific-Asia has shown tremendous growth during the forecast period, the markets in the Africa and middle-east has the lowest growth rated due to the unavailability or limited access to the treatment facilities. The developing healthcare infrastructure is the major cause for the rise in growth of the market in middle-east and Africa. 


Competitive landscape:
The share, growth and influenza vaccine market size, surveys the scenarios of the market by analyzing the key players. The different strategies adopted by different companies for the extension of the business, among which mergers, acquisions and other measures of business are included. The financial framework includes profit, sales, and the revenue generated by the market’s key players.


The major key player of the influenza vaccine markets are as follows:



  •         AstraZenca (UK)

  •         GlazoSmithKline PLC (UK)

  •         Sanofi(France)

  •         Abbott Laboratories (US)

  •         Seqirus (UK)

  •         Hualan Biological Engineering Inc. (China)

  •         Mitsubishi Tanabe Pharma (Japan)

  •         Serum Institute of India Pvt. Ltd (India)

  •         Mylan NV (US)


Recent Developments


  • Recently, several new novel formulations have been tested. These formulations contain ranges of high doses of vaccines for the older people or people ages 65 or more and other adjuvented vaccines are MF59 AND AS03.

  • These new formulation has increased the efficiency of the vaccines. MF59 is a seasonal vaccine for the older people and it is licensed and marked in more than 25 countries, in the name of the brand Flaud. AS03 is still under constructions.


Report Overview:
The following report comprises of –



  •         Market overview

  •         Covid 19 Analysis

  •         Market Dynamic

  •         Drivers

  •         Opportunities

  •         Restraints

  •         Challenges

  •         Cumulative Growth Analysis

  •         Value Chain Analysis

  •         Segmentation Overview

  •         By Application

  •         By End-Users

  •         Regional Analysis

  •         Competitive landscape

  •         Recent Developments


This report is to point out the high points of the global flu vaccine market in terms of the revenue hike by end of the global forecast year 2025.


Market Segmentation:
Global Influenza Vaccines Market, by Influenza Type



  •         Seasonal

  •         zoonotic


GlGlobal Influenza Vaccines Market, by Manufacturing Technology



  •         Egg-based

  •         Cell culture based

  •         Recombinant base


Global Influenza Vaccines Market, by Vaccine Type



  •         Quadrivalent Influenza Vaccines

  •         Trivalant Influenza Vaacines


Global Influenza Vaccines Market, by End User



  •         Hospitals & Clinics

  •         Research Organizations & Academic Institutes

  •         Others


Global Influenza Vaccines Market, by Region



  •         Americas

  •         North America

  •         South America

  •         Europe

  •         UK

  •         France

  •         Germany

  •         Russia

  •         Italy

  •         Rest of Europe

  •         Asia-Pacific

  •         China

  •         India

  •         Australia

  •         New Zealand

  •         Rest of Asia-Pacific

  •         Middle East & Africa

  •         Saudi Arabia

  •         UAE

  •         Egypt

  •         Kuwait

  •         South Africa

  •         Oman

  •         Rest of Middle East & Africa

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION 17

2.2 SCOPE OF THE STUDY 17

2.3 RESEARCH OBJECTIVE 17

2.4 MARKET STRUCTURE 18

2.5 ASSUMPTIONS & LIMITATIONS 19

3 RESEARCH METHODOLOGY

3.1 DATA MINING 20

3.2 SECONDARY RESEARCH 21

3.3 PRIMARY RESEARCH 22

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24

3.5 FORECASTING TECHNIQUES 25

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26

3.6.1 BOTTOM-UP APPROACH 27

3.6.2 TOP-DOWN APPROACH 27

3.7 DATA TRIANGULATION 28

3.8 VALIDATION 28

4 MARKET DYNAMICS

4.1 OVERVIEW 29

4.2 DRIVERS 30

4.2.1 RISING PREVALENCE OF INFLUENZA 30

4.2.2 INCREASING PUBLIC AND PRIVATE INITIATIVES FOR RESEARCH AND DEVELOPMENT 30

4.2.3 GROWING AWARENESS ABOUT INFLUENZA VACCINES 31

4.2.4 INCREASING PRODUCT LAUNCHES AND APPROVALS 31

4.3 RESTRAINTS 33

4.3.1 STRINGENT REGULATORY POLICIES 33

4.3.2 PRODUCT RECALLS AND CLINICAL TRIAL SUSPENSION 33

4.4 OPPORTUNITIES 34

4.4.1 INCREASING NUMBER OF CLINICAL TRIAL CANDIDATES 34

4.5 MARKET TRENDS 34

4.5.1 AMERICAS 34

4.5.2 EUROPE 35

4.5.3 ASIA-PACIFIC 35

4.5.4 MIDDLE EAST & AFRICA 35

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 36

5.1.1 BARGAINING POWER OF SUPPLIERS 36

5.1.2 BARGAINING POWER OF BUYERS 37

5.1.3 THREAT OF NEW ENTRANTS 37

5.1.4 THREAT OF SUBSTITUTES 37

5.1.5 INTENSITY OF RIVALRY 37

5.2 VALUE CHAIN ANALYSIS 38

5.2.1 R&D 39

5.2.2 MANUFACTURING 39

5.2.3 DISTRIBUTION 39

5.2.4 MARKETING & SALES 39

5.3 INVESTMENT SCENARIO 40

5.3.1 INVESTMENT OPPORTUNITY 40

5.3.2 INVESTMENTS BY MAJOR MARKET PLAYERS 41

5.4 PRODUCTION CAPACITY 41

6 GLOBAL INFLUENZA VACCINES MARKET BY INFLUENZA TYPE

6.1 OVERVIEW 42

6.2 SEASONAL 43

6.3 ZOONOTIC 44

7 GLOBAL INFLUENZA VACCINES MARKET BY MANUFACTURING TECHNOLOGY

7.1 OVERVIEW 45

7.2 EGG-BASED 46

7.3 CELL CULTURE-BASED 47

7.4 RECOMBINANT-BASED 48

8 GLOBAL INFLUENZA VACCINES MARKET BY VACCINE TYPE

8.1 OVERVIEW 49

8.2 QUADRIVALENT INFLUENZA VACCINES 50

8.3 TRIVALENT INFLUENZA VACCINES 51

9 GLOBAL INFLUENZA VACCINES MARKET BY END USER

9.1 OVERVIEW 52

9.2 HOSPITALS & CLINICS 53

9.3 RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES 54

9.4 OTHERS 54

10 GLOBAL INFLUENZA VACCINES MARKET BY REGION

10.1 OVERVIEW 55

10.2 AMERICAS 57

10.2.1 NORTH AMERICA 60

10.2.2 SOUTH AMERICA 62

10.3 EUROPE 64

10.3.1 UK 67

10.3.2 FRANCE 69

10.3.3 GERMANY 71

10.3.4 RUSSIA 73

10.3.5 ITALY 75

10.3.6 REST OF EUROPE 77

10.4 ASIA-PACIFIC 79

10.4.1 CHINA 82

10.4.2 INDIA 84

10.4.3 AUSTRALIA 86

10.4.4 NEW ZEALAND 88

10.4.5 REST OF ASIA-PACIFIC 90

10.5 MIDDLE EAST & AFRICA 92

10.5.1 SAUDI ARABIA 95

10.5.2 UAE 97

10.5.3 EGYPT 99

10.5.4 KUWAIT 101

10.5.5 SOUTH AFRICA 103

10.5.6 OMAN 105

10.5.7 REST OF MIDDLE EAST & AFRICA 107

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 109

11.2 COMPANY SHARE ANALYSIS 109

11.3 COMPETITIVE BENCHMARKING 111

11.4 COMPETITOR DASHBOARD 112

11.5 MAJOR GROWTH STRATEGY IN THE GLOBAL INFLUENZA VACCINES MARKET 113

11.6 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL INFLUENZA VACCINES MARKET 114

11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 114

11.7.1 PRODUCT APPROVALS 115

11.7.2 EXPANSIONS & INVESTMENTS 115

11.7.3 ACQUISITIONS 116

11.7.4 COLLABORATIONS 116

12 COMPANY PROFILE

12.1 ASTRAZENECA 117

12.1.1 COMPANY OVERVIEW 117

12.1.2 FINANCIAL OVERVIEW 117

12.1.3 PRODUCTS/SERVICES OFFERED 118

12.1.4 KEY DEVELOPMENTS 118

12.1.5 SWOT ANALYSIS 119

12.1.6 KEY STRATEGIES 119

12.2 GLAXOSMITHKLINE PLC 120

12.2.1 COMPANY OVERVIEW 120

12.2.2 FINANCIAL OVERVIEW 120

12.2.3 PRODUCTS/SERVICES OFFERED 121

12.2.4 KEY DEVELOPMENTS 121

12.2.5 SWOT ANALYSIS 122

12.2.6 KEY STRATEGIES 122

12.3 SANOFI 123

12.3.1 COMPANY OVERVIEW 123

12.3.2 FINANCIAL OVERVIEW 123

12.3.3 PRODUCTS/SERVICES OFFERED 124

12.3.4 KEY DEVELOPMENTS 124

12.3.5 SWOT ANALYSIS 125

12.3.6 KEY STRATEGIES 125

12.4 ABBOTT LABORATORIES 126

12.4.1 COMPANY OVERVIEW 126

12.4.2 FINANCIAL OVERVIEW 126

12.4.3 PRODUCTS/SERVICES OFFERED 127

12.4.4 KEY DEVELOPMENTS 127

12.4.5 SWOT ANALYSIS 127

12.4.6 KEY STRATEGIES 128

12.5 SEQIRUS 129

12.5.1 COMPANY OVERVIEW 129

12.5.2 FINANCIAL OVERVIEW 130

12.5.3 PRODUCTS/SERVICES OFFERED 130

12.5.4 KEY DEVELOPMENTS 131

12.5.5 SWOT ANALYSIS 132

12.5.6 KEY STRATEGIES 132

12.6 HUALAN BIOLOGICAL ENGINEERING INC. 133

12.6.1 COMPANY OVERVIEW 133

12.6.2 FINANCIAL OVERVIEW 133

12.6.3 PRODUCTS/SERVICES OFFERED 133

12.6.4 KEY DEVELOPMENTS 133

12.6.5 SWOT ANALYSIS 134

12.6.6 KEY STRATEGIES 134

12.7 MITSUBISHI TANABE PHARMA 135

12.7.1 COMPANY OVERVIEW 135

12.7.2 FINANCIAL OVERVIEW 135

12.7.3 PRODUCTS/SERVICES OFFERED 136

12.7.4 KEY DEVELOPMENTS 136

12.7.5 SWOT ANALYSIS 137

12.7.6 KEY STRATEGIES 137

12.8 SERUM INSTITUTE OF INDIA PVT. LTD 138

12.8.1 COMPANY OVERVIEW 138

12.8.2 FINANCIAL OVERVIEW 138

12.8.3 PRODUCTS/SERVICES OFFERED 138

12.8.4 KEY DEVELOPMENTS 138

12.8.5 SWOT ANALYSIS 139

12.8.6 KEY STRATEGIES 139

12.9 MYLAN NV 140

12.9.1 COMPANY OVERVIEW 140

12.9.2 FINANCIAL OVERVIEW 140

12.9.3 PRODUCTS/SERVICES OFFERED 141

12.9.4 KEY DEVELOPMENTS 141

12.9.5 SWOT ANALYSIS 141

12.9.6 KEY STRATEGIES 142

13 APPENDIX

13.1 REFERENCES 143

13.2 RELATED REPORTS 143

14 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 19

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23

TABLE 3 GLOBAL INFLUENZA PRODUCTION CAPACITY, 2020 41

TABLE 4 GLOBAL INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 43

TABLE 5 GLOBAL INFLUENZA VACCINES MARKET, FOR SEASONAL, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 6 GLOBAL INFLUENZA VACCINES MARKET, FOR ZOONOTIC, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 7 GLOBAL INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 46

TABLE 8 GLOBAL INFLUENZA VACCINES MARKET, FOR EGG-BASED, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 9 GLOBAL INFLUENZA VACCINES MARKET, FOR CELL CULTURE-BASED, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 10 GLOBAL INFLUENZA VACCINES MARKET, FOR RECOMBINANT-BASED, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 11 GLOBAL INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 50

TABLE 12 GLOBAL INFLUENZA VACCINES MARKET, FOR QUADRIVALENT INFLUENZA VACCINES, BY REGION, 2020–2027 (USD MILLION) 50

TABLE 13 GLOBAL INFLUENZA VACCINES MARKET, FOR TRIVALENT INFLUENZA VACCINES, BY REGION, 2020–2027 (USD MILLION) 51

TABLE 14 GLOBAL INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 53

TABLE 15 GLOBAL INFLUENZA VACCINES MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION) 53

TABLE 16 GLOBAL INFLUENZA VACCINES MARKET, FOR RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES, BY REGION,

2020–2027 (USD MILLION) 54

TABLE 17 GLOBAL INFLUENZA VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 18 AMERICAS: INFLUENZA VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 58

TABLE 19 AMERICAS: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 58

TABLE 20 AMERICAS: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 58

TABLE 21 AMERICAS: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 59

TABLE 22 AMERICAS: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 59

TABLE 23 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 60

TABLE 24 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 60

TABLE 25 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 61

TABLE 26 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 61

TABLE 27 SOUTH AMERICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 62

TABLE 28 SOUTH AMERICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 62

TABLE 29 SOUTH AMERICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 63

TABLE 30 SOUTH AMERICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 31 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65

TABLE 32 EUROPE: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 65

TABLE 33 EUROPE: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 66

TABLE 34 EUROPE: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 66

TABLE 35 EUROPE: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 36 UK: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 67

TABLE 37 UK: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 68

TABLE 38 UK: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 68

TABLE 39 UK: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 68

TABLE 40 FRANCE: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 69

TABLE 41 FRANCE: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 69

TABLE 42 FRANCE: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 70

TABLE 43 FRANCE: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 70

TABLE 44 GERMANY: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 71

TABLE 45 GERMANY: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 71

TABLE 46 GERMANY: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 72

TABLE 47 GERMANY: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 48 RUSSIA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 73

TABLE 49 RUSSIA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 73

TABLE 50 RUSSIA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 74

TABLE 51 RUSSIA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 74

TABLE 52 ITALY: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 75

TABLE 53 ITALY: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 75

TABLE 54 ITALY: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 76

TABLE 55 ITALY: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 76

TABLE 56 REST OF EUROPE: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 77

TABLE 57 REST OF EUROPE: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 77

TABLE 58 REST OF EUROPE: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 78

TABLE 59 REST OF EUROPE: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 60 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80

TABLE 61 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 80

TABLE 62 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 80

TABLE 63 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 81

TABLE 64 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 81

TABLE 65 CHINA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 82

TABLE 66 CHINA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 82

TABLE 67 CHINA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 83

TABLE 68 CHINA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 83

TABLE 69 INDIA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 84

TABLE 70 INDIA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 84

TABLE 71 INDIA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 85

TABLE 72 INDIA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 85

TABLE 73 AUSTRALIA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 86

TABLE 74 AUSTRALIA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 86

TABLE 75 AUSTRALIA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 87

TABLE 76 AUSTRALIA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 87

TABLE 77 NEW ZEALAND: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 88

TABLE 78 NEW ZEALAND: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 88

TABLE 79 NEW ZEALAND: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 89

TABLE 80 NEW ZEALAND: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 89

TABLE 81 REST OF ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 90

TABLE 82 REST OF ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 90

TABLE 83 REST OF ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 91

TABLE 84 REST OF ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 91

TABLE 85 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93

TABLE 86 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 93

TABLE 87 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 94

TABLE 88 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 94

TABLE 89 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 94

TABLE 90 SAUDI ARABIA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 95

TABLE 91 SAUDI ARABIA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 95

TABLE 92 SAUDI ARABIA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 96

TABLE 93 SAUDI ARABIA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 96

TABLE 94 UAE: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 97

TABLE 95 UAE: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 97

TABLE 96 UAE: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 98

TABLE 97 UAE: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 98

TABLE 98 EGYPT: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 99

TABLE 99 EGYPT: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 99

TABLE 100 EGYPT: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 100

TABLE 101 EGYPT: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 100

TABLE 102 KUWAIT: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 101

TABLE 103 KUWAIT: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 101

TABLE 104 KUWAIT: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 102

TABLE 105 KUWAIT: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 102

TABLE 106 SOUTH AFRICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 103

TABLE 107 SOUTH AFRICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 103

TABLE 108 SOUTH AFRICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 104

TABLE 109 SOUTH AFRICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 104

TABLE 110 OMAN: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 105

TABLE 111 OMAN: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020–2027 (USD MILLION) 105

TABLE 112 OMAN: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 106

TABLE 113 OMAN: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 106

TABLE 114 REST OF MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020–2027 (USD MILLION) 107

TABLE 115 REST OF MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY,

2020–2027 (USD MILLION) 107

TABLE 116 REST OF MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020–2027 (USD MILLION) 108

TABLE 117 REST OF MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY END USER, 2020–2027 (USD MILLION) 108

TABLE 118 THE MOST ACTIVE PLAYER IN THE GLOBAL INFLUENZA VACCINES MARKET 114

TABLE 119 PRODUCT APPROVALS 115

TABLE 120 EXPANSIONS 115

TABLE 121 INVESTMENTS 116

TABLE 122 ACQUISITIONS 116

TABLE 123 COLLABORATIONS 116

TABLE 124 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 118

TABLE 125 ASTRAZENECA: KEY DEVELOPMENTS 118

TABLE 126 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 121

TABLE 127 GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS 121

TABLE 128 SANOFI: PRODUCTS/SERVICES OFFERED 124

TABLE 129 SANOFI: KEY DEVELOPMENTS 124

TABLE 130 ABBOTT LABORATORIES: PRODUCTS/SERVICES OFFERED 127

TABLE 131 ABBOTT LABORATORIES: KEY DEVELOPMENTS 127

TABLE 132 SEQIRUS: PRODUCTS/SERVICES OFFERED 130

TABLE 133 SEQIRUS: KEY DEVELOPMENTS 131

TABLE 134 HUALAN BIOLOGICAL ENGINEERING INC.: PRODUCTS/SERVICES OFFERED 133

TABLE 135 HUALAN BIOLOGICAL ENGINEERING INC.: KEY DEVELOPMENTS 133

TABLE 136 MITSUBISHI TANABE PHARMA: PRODUCTS/SERVICES OFFERED 136

TABLE 137 MITSUBISHI TANABE PHARMA: KEY DEVELOPMENTS 136

TABLE 138 SERUM INSTITUTE OF INDIA PVT. LTD: PRODUCTS/SERVICES OFFERED 138

TABLE 139 MYLAN NV: PRODUCTS/SERVICES OFFERED 141

TABLE 140 MYLAN NV: KEY DEVELOPMENTS 141

15 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 16

FIGURE 2 GLOBAL INFLUENZA VACCINES MARKET: STRUCTURE 18

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 26

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL INFLUENZA VACCINES MARKET 29

FIGURE 5 DRIVER IMPACT ANALYSIS 32

FIGURE 6 RESTRAINT IMPACT ANALYSIS 33

FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL INFLUENZA VACCINES MARKET 36

FIGURE 8 VALUE CHAIN ANALYSIS OF THE GLOBAL INFLUENZA VACCINES MARKET 38

FIGURE 9 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY INFLUENZA TYPE, 2020 (%) 42

FIGURE 10 GLOBAL INFLUENZA VACCINES MARKET, BY INFLUENZA TYPE, 2020 AND 2027 (USD MILLION) 42

FIGURE 11 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY MANUFACTURING TECHNOLOGY, 2020 (%) 45

FIGURE 12 GLOBAL INFLUENZA VACCINES MARKET, BY MANUFACTURING TECHNOLOGY, 2020 AND 2027 (USD MILLION) 45

FIGURE 13 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY VACCINE TYPE, 2020 (%) 49

FIGURE 14 GLOBAL INFLUENZA VACCINES MARKET, BY VACCINE TYPE, 2020 AND 2027 (USD MILLION) 49

FIGURE 15 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY END USER, 2020 (%) 52

FIGURE 16 GLOBAL INFLUENZA VACCINES MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 52

FIGURE 17 GLOBAL INFLUENZA VACCINES MARKET SHARE, BY REGION, 2020 (%) 55

FIGURE 18 GLOBAL INFLUENZA VACCINES MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 55

FIGURE 19 AMERICAS: INFLUENZA VACCINES MARKET, BY REGION, 2020 AND 2027 57

FIGURE 20 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020 AND 2027 64

FIGURE 21 ASIA-PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020 AND 2027 79

FIGURE 22 MIDDLE EAST & AFRICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2020 AND 2027 92

FIGURE 23 GLOBAL INFLUENZA VACCINES MARKET SHARE ANALYSIS, 2020 (%) 109

FIGURE 24 BENCHMARKING OF MAJOR COMPETITORS 111

FIGURE 25 COMPETITOR DASHBOARD: GLOBAL INFLUENZA VACCINES MARKET 112

FIGURE 26 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE INFLUENZA VACCINES MARKET 113

FIGURE 27 GLOBAL INFLUENZA VACCINE MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 114

FIGURE 28 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 117

FIGURE 29 ASTRAZENECA: SWOT ANALYSIS 119

FIGURE 30 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 120

FIGURE 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 122

FIGURE 32 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 123

FIGURE 33 SANOFI: SWOT ANALYSIS 125

FIGURE 34 ABBOTT LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 126

FIGURE 35 ABBOTT LABORATORIES: SWOT ANALYSIS 127

FIGURE 36 CSL LIMITED: FINANCIAL OVERVIEW SNAPSHOT 130

FIGURE 37 SEQIRUS: SWOT ANALYSIS 132

FIGURE 38 HUALAN BIOLOGICAL ENGINEERING INC.: SWOT ANALYSIS 134

FIGURE 39 MITSUBISHI TANABE PHARMA: FINANCIAL OVERVIEW SNAPSHOT 135

FIGURE 40 MITSUBISHI TANABE PHARMA: SWOT ANALYSIS 137

FIGURE 41 SERUM INSTITUTE OF INDIA PVT. LTD: SWOT ANALYSIS 139

FIGURE 42 MYLAN NV: FINANCIAL OVERVIEW SNAPSHOT 140

FIGURE 43 MYLAN NV: SWOT ANALYSIS 141